SK Bioscience Co (XKRX:302440) Interest Expense : ₩-3,685 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. SK Bioscience Co's interest expense for the three months ended in Dec. 2024 was ₩ -2,971 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-3,685 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. SK Bioscience Co's Operating Income for the three months ended in Dec. 2024 was ₩ -50,776 Mil. SK Bioscience Co's Interest Expense for the three months ended in Dec. 2024 was ₩ -2,971 Mil. SK Bioscience Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SK Bioscience Co Interest Expense Historical Data

The historical data trend for SK Bioscience Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Interest Expense Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-4,150.69

-3,426.93

-2,460.94

-1,398.14

-3,684.91

SK Bioscience Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-261.42	-262.05	-238.36	-213.83	-2,970.68

SK Bioscience Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,685 Mil.

SK Bioscience Co (XKRX:302440) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SK Bioscience Co's Interest Expense for the three months ended in Dec. 2024 was ₩-2,971 Mil. Its Operating Income for the three months ended in Dec. 2024 was ₩-50,776 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was ₩385,857 Mil.

SK Bioscience Co's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

SK Bioscience Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

SK Bioscience Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co Headlines

No Headlines